Opportunities Abound

Attendees awoke to the news this morning about GlaxoSmithKline’s announcement that it will pay millions — $720 million to be exact — for Sirtris Pharmaceuticals. This is the stuff biotech CEOs dream about. And it was the buzz at many breakfast tables at this morning’s workshop, “Antibiotics: Bad Bugs – Few Drugs.”
The BNVC meeting, of [...]

BIO National Venture Conference Off to a Strong Start

While the economy may not be as robust as it has in recent years, there certainly was no sign of that at today’s Opening Luncheon. Jim Greenwood, our President & CEO welcomed attendees to the inaugural BIO National Venture Conference and cited these impressive stats:

140 top-level (VP and higher) venture capitalists – including 4 international investors – [...]

Welcome to Boston!

The marathon may be over, but that doesn’t mean there isn’t plenty more activity going on here in Boston.    We’re here in Cambridge, one of biotechnology’s “hot-spots” for the inaugural BIO National Venture Conference meeting up with some of the newest early stage and seed stage companies seeking venture funding.  Stay tuned for more as the [...]